Identification of heat shock protein 90 inhibitors to sensitize drug resistant side population tumor cells using a cell based assay platform

Cancer Letters

Volumn 317, Issue 1, 2012, Pages 78-88

  Sobhan, Praveen K ^a   Seervi, Mahendra ^a   Joseph, Jeena ^a   Chandrika, Bhavya Balan ^a   Varghese, Saneesh ^a   Santhoshkumar, T R ^a   Radhakrishna Pillai, M ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Apoptosis; Cancer stem cells; Cytochrome C EGFP; Drug screening; Side population cells

Indexed keywords

ALVESPIMYCIN; CISPLATIN; COLCHICINE; CYTOCHROME C; FLUOROURACIL; HEAT SHOCK PROTEIN 90 INHIBITOR; SURVIVIN; TANESPIMYCIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CHROMATIN CONDENSATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME RELEASE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGING; MITOCHONDRIAL MEMBRANE POTENTIAL; PLASMID; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIDE POPULATION CELL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTOCHROMES C; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HCT116 CELLS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MITOCHONDRIA; NEOPLASTIC STEM CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS; SIDE-POPULATION CELLS; TRANSFECTION;

EID: 84856358836     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.009     Document Type: Article

References (38)

1. Massard C., Deutsch E., Soria J.C. Tumour stem cell-targeted treatment: elimination or differentiation. Ann. Oncol. 2006, 17:1620-1624.
2. Ignatova T.N., Kukekov V.G., Laywell E.D., Suslov O.N., Vrionis F.D., Steindler D.A. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002, 39:193-206.
3. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
4. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Goodell M.A., Brenner M.K. A distinct " side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101:14228-14233.
5. Kondo T., Setoguchi T., Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. USA 2004, 101:781-786.
6. Olempska M., Eisenach P.A., Ammerpohl O., Ungefroren H., Fandrich F., Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat. Dis. Int. 2007, 6:92-97.
7. Chen J., Chen Z.L. Technology update for the sorting and identification of breast cancer stem cells. Chin. J. Cancer 2010, 29:265-269.
8. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
9. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
10. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
11. Diehn M., Clarke M.F. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J. Natl. Cancer Inst. 2006, 98:1755-1757.
12. Chiba T., Kita K., Zheng Y.W., Yokosuka O., Saisho H., Iwama A., Nakauchi H., Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
13. Haraguchi N., Utsunomiya T., Inoue H., Tanaka F., Mimori K., Barnard G.F., Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24:506-513.
14. Mitsutake N., Iwao A., Nagai K., Namba H., Ohtsuru A., Saenko V., Yamashita S. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007, 148:1797-1803.
15. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., Dinulescu D.M., Connolly D., Foster R., Dombkowski D., Preffer F., Maclaughlin D.T., Donahoe P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. USA 2006, 103:11154-11159.
16. Feuring-Buske M., Hogge D.E. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 2001, 97:3882-3889.
17. Wulf G.G., Wang R.Y., Kuehnle I., Weidner D., Marini F., Brenner M.K., Andreeff M., Goodell M.A. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98:1166-1173.
18. Achuthan S., Santhoshkumar T.R., Prabhakar J., Nair S.A., Pillai M.R. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J. Biol. Chem. 2011, 286:37813-37829.
19. B.B. Chandrika, S.K. Maney, S.U. Lekshmi, J. Joseph, M. Seervi, S.P. K, R.S. T, Bax deficiency mediated drug resistance can be reversed by endoplasmic reticulum stress induced death signaling, Biochem. Pharmacol. 79 (2010) 1589-1599.
20. Seervi M., Joseph J., Sobhan P.K., Bhavya B.C., Santhoshkumar T.R. Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models. Cell Death Dis. 2011, 2:e207.
21. Goodell M.A. Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr. Prot. Cytom. 2005, 18. (Chapter 9) (Unit 9).
22. Goldstein J.C., Munoz-Pinedo C., Ricci J.E., Adams S.R., Kelekar A., Schuler M., Tsien R.Y., Green D.R. Cytochrome c is released in a single step during apoptosis. Cell Death Differ. 2005, 12:453-462.
23. Miyauchi H., Minamino T., Tateno K., Kunieda T., Toko H., Komuro I. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J. 2004, 23:212-220.
24. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., Holland E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
25. Mogi M., Yang J., Lambert J.F., Colvin G.A., Shiojima I., Skurk C., Summer R., Fine A., Quesenberry P.J., Walsh K. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J. Biol. Chem. 2003, 278:39068-39075.
26. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.M., Garcia-Echeverria C., Schultz P.G., Reddy V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 2009, 106:268-273.
27. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
28. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3:895-902.
29. Tang D.G., Patrawala L., Calhoun T., Bhatia B., Choy G., Schneider-Broussard R., Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinog. 2007, 46:1-14.
30. Shi G.M., Xu Y., Fan J., Zhou J., Yang X.R., Qiu S.J., Liao Y., Wu W.Z., Ji Y., Ke A.W., Ding Z.B., He Y.Z., Wu B., Yang G.H., Qin W.Z., Zhang W., Zhu J., Min Z.H., Wu Z.Q. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 2008, 134:1155-1163.
31. Birnie R., Bryce S.D., Roome C., Dussupt V., Droop A., Lang S.H., Berry P.A., Hyde C.F., Lewis J.L., Stower M.J., Maitland N.J., Collins A.T. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 2008, 9:R83.
32. Peacock C.D., Wang Q., Gesell G.S., Corcoran-Schwartz I.M., Jones E., Kim J., Devereux W.L., Rhodes J.T., Huff C.A., Beachy P.A., Watkins D.N., Matsui W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. USA 2007, 104:4048-4053.
33. Tothova Z., Gilliland D.G. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007, 1:140-152.
34. Neckers L. Heat shock protein 90: the cancer chaperone. J. Biosci. 2007, 32:517-530.
35. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad. Sci. 2007, 1113:202-216.
36. Barginear M.F., Van Poznak C., Rosen N., Modi S., Hudis C.A., Budman D.R. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr. Cancer Drug Targets 2008, 8:522-532.
37. Bishop S.C., Burlison J.A., Blagg B.S. Hsp90: a novel target for the disruption of multiple signaling cascades. Curr. Cancer Drug Targets 2007, 7:369-388.
38. Sain N., Krishnan B., Ormerod M.G., De Rienzo A., Liu W.M., Kaye S.B., Workman P., Jackman A.L. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol. Cancer Ther. 2006, 5:1197-1208.